Senile plaques, a major neuropathologic feature of Alzheimer's disease (AD), are composed largely of the amyloid peptide (Abeta) that is derived by processing of the amyloid precursor protein (APP). The two major forms of amyloid are 40 and 42 amino acid long. While Abeta(1-40) is more abundant, Abeta(1-40) aggregates more readily and comprises the majority of the amyloid in SPs. Mutations in APP that are associated with familial AD (FAD) alter the Abeta production by increasing the total amount of Abeta generated, or by causing a relative increase in the amount of Abeta(1-40) produced. Thus, perturbations in APP processing and Abeta production may play an important role in the development of AD. Therefore, the goals of Project 1 are to continue delineation of APP processing pathways in human neuronal model system (NT2N cells). We recently found that retention of APP in the endoplasmic reticulum/intermediate compartment (ER/IC) blocked Abeta secretion, but intracellular Abeta was still produced. Quantitative ELISA showed that ER/IC-associated Abeta is composed exclusively of Abeta(1-42). This intra-neuronal Abeta(1-42) accumulates over a period of weeks in NT2N while becoming less soluble. These observations have implications for understanding AD pathogenesis, including possible links to the presenilins (i.e., PS1 and PS2) which are membrane proteins largely localized to the ER/IC that cause AD when they are mutated in FAD pedigrees. Interestingly, FAD-associated forms of mutant the presenilins increased the levels of Abeta(1-42). Long-term accumulation of aggregated intra-neuronal Abeta(1-42) might be neurotoxic and ultimately lead to the formation of SPs following neuronal death. We propose to extend our studies on this novel pathway, to examine other subcellular compartments where Abeta is produced, and to study the effects of the presenilins on Abeta production through the following Specific Aims: 1) to continue our recent studies on the ER/IC pathway by which intracellular Abeta(1-42) is produced; 2) to study potential interactions between the presenilins and APP, and examine how expression of wild type or mutant PS1 and PS affects intracellular Abeta production; 3) to examine the role of the endocytic pathway in the production of intracellular and secreted Abeta(1-40) and Abeta(1-42); and 4) to study how wild-type and mutant forms of APP751 AND 770 are processed by NT2N neurons.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011542-09
Application #
6485946
Study Section
Project Start
2001-09-01
Project End
2002-08-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
2001
Total Cost
$196,218
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Hurtado, David E; Molina-Porcel, Laura; Carroll, Jenna C et al. (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 32:7392-402
Xu, Shaohua; Brunden, Kurt R; Trojanowski, John Q et al. (2010) Characterization of tau fibrillization in vitro. Alzheimers Dement 6:110-7
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Hurtado, David E; Molina-Porcel, Laura; Iba, Michiyo et al. (2010) A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177:1977-88
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Chen, Xiao-Han; Johnson, Victoria E; Uryu, Kunihiro et al. (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19:214-23
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Shineman, Diana W; Dain, Aleksandra S; Kim, Minkyu L et al. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48:3787-94
Kim, Minkyu L; Zhang, Bin; Mills, Ian P et al. (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28:12052-61

Showing the most recent 10 out of 94 publications